• Users Online: 551
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 4  |  Issue : 3  |  Page : 123-128

Placebo response in clinical trials: Taming the human brain

1 Medical Writing, Tata Consultancy Services, Noida, India
2 Department of Physiology, All Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Raj Kumar Yadav
Department of Physiology, All India Institute of Medical Sciences, New Delhi - 110 029
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijcep.ijcep_36_17

Rights and Permissions

The use of placebo in comparative clinical trials has exposed another lesser known side of the placebo, i.e., the placebo response. The placebo response is now being increasingly discussed, not only to adjust for the true clinical efficacy of a drug but also to understand the basis of psychological therapy, and benefits in therapeutic areas such as neurological disorders, especially pain. The mechanism of placebo action is multifaceted and works on the levels of brain and biochemical signaling, stimulated by priming and expectations. The imaging data show that certain areas of the brain are hyperactive while some are hypoactive during the placebo-mediated response, and trigger a biochemical pathway that relieves the symptoms. The data also suggest that the extent of benefit, i.e., the effect size of placebo response is directly proportional to positive expectations associated with the treatment, trust on the treating doctor, and certain beliefs associated with previous treatment. Although placebos incite a positive response, these might compromise or artifact the true efficacy of the drugs, thereby necessitating the need of addressing or minimizing the placebo response. Furthermore, it is important to identify the factors that modulate the placebo response, such as severity and natural burning out of the disease. Therefore, it is important to take a two-pronged approach- first, placebo as a treatment, for example, in neurological diseases, and second, adequately designed studies that minimize the placebo response. In this article, we discuss the placebo response, the mechanism behind it, its implications in clinical trials, and how to address the same.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded108    
    Comments [Add]    

Recommend this journal